CAPITAL RESOURCES 10 • the costs involved in filing patent applications and maintaining 10.4.3 CAPITAL EXPENDITURES and enforcing patents or defending against claims of Our main capital expenditures in 2016 and 2017 were primarily infringement raised by third-parties; related to leasehold improvements and office and IT equipment • the time and costs involved in obtaining regulatory approval for for our headquarters and to license and software fees. Clinical our product candidates and any delays we may encounter as a research and development costs are not capitalized until result of evolving regulatory requirements or adverse results marketing authorizations are obtained. with respect to any of these product candidates; • sel ling and marketing activities undertaken in connection As of December 31, with the anticipated commercialization of the GS010 product 2016 2017 candidate and any other current or future product candidates, K€ K€ including GS030 and other product candidates in preclinical Licenses, software 1 – development, together with the costs involved in the creation Property, plant and equipment 188 236 of an effective sales and marketing organization; and Non-current financial assets (8) – • the amount of revenues, if any, we may derive either directly, Total 181 236 or in the form of royalty payments from any future potential partnership agreements, on the GS010 platform or relating to In 2017, our capital expenditures primarily related to acquiring our other product candidates. technical equipment €(95 K), leasehold improvement €(51 K), furniture €(47 K) and computer equipment €(41 K). For more information as to the risks associated with our future funding needs, see the section of this Registration Document As of December 31, 2017, we had no material contractual entitled Section 4 “Risk Factors.” commitments to acquire property, plant or equipment. GENSIGHT BIOLOGICS – 2017 Registration Document– 127